Loading...
The aromatase inhibitor exemestane — used to treat early breast cancer in postmenopausal women and being considered for use in preventing the disease — worsens age-related bone loss, a Lancet Oncology study finds.
Researchers randomized some 350 women to receive exemestane or placebo. All were at increased risk for breast cancer, had no clinical evidence of bone-related disorders, and received calcium and vitamin D supplements.
After 2 years of treatment, the decline in bone-mineral density at the distal radius (the study's primary endpoint) was 6.1% among exemestane recipients versus 1.8% among placebo recipients. Secondary endpoints, including density at the distal tibia and cortical thickness at the distal radius and tibia, showed similar changes.
The authors say the observed effects were likely secondary to loss of estrogen. And a commentator concludes: "Thus, one might not be too reassured about the use of exemestane in the prevention setting."
Comment
LINK(S):
Lancet Oncology article (Free abstract)
Lancet Oncology comment (Subscription required)
Physician's First Watch coverage of report showing exemestane's breast cancer prevention benefit (Free)